DAG1 and rhabdomyosarcoma: To determine whether the lack of matriglycan immunoreactivity in rhabdomyosarcomas reflects the loss of the core α-dystroglycan protein or a defect in its processing, we next analyzed RMS tumors by immunoblotting.